Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
4.400
-0.040 (-0.90%)
At close: Apr 28, 2026, 4:00 PM EDT
4.490
+0.090 (2.05%)
After-hours: Apr 28, 2026, 7:31 PM EDT
Larimar Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 18.87 | 18.11 | 14.49 | 12.28 | 12.07 | |
| Research & Development | 153.62 | 72.78 | 27.27 | 24.25 | 38.4 | |
| Operating Expenses | 172.5 | 90.89 | 41.76 | 36.53 | 50.47 | |
| Operating Income | -172.5 | -90.89 | -41.76 | -36.53 | -50.47 | |
| Other Non Operating Income (Expenses) | 6.82 | 10.29 | 4.81 | 1.17 | -0.17 | |
| Pretax Income | -165.67 | -80.6 | -36.95 | -35.36 | -50.64 | |
| Net Income | -165.67 | -80.6 | -36.95 | -35.36 | -50.64 | |
| Net Income to Common | -165.67 | -80.6 | -36.95 | -35.36 | -50.64 | |
| Shares Outstanding (Basic) | 73 | 61 | 44 | 26 | 17 | |
| Shares Outstanding (Diluted) | 73 | 61 | 44 | 26 | 17 | |
| Shares Change (YoY) | 19.09% | 39.53% | 70.42% | 50.09% | 44.44% | |
| EPS (Basic) | -2.27 | -1.32 | -0.84 | -1.37 | -2.95 | |
| EPS (Diluted) | -2.27 | -1.32 | -0.84 | -1.37 | -2.95 | |
| Free Cash Flow | -113.29 | -71.28 | -33.62 | -27.67 | -42.44 | |
| Free Cash Flow Per Share | -1.55 | -1.16 | -0.77 | -1.07 | -2.47 | |
| EBITDA | -172.15 | -90.57 | -41.45 | -36.21 | -50.14 | |
| D&A For EBITDA | 0.35 | 0.32 | 0.31 | 0.32 | 0.33 | |
| EBIT | -172.5 | -90.89 | -41.76 | -36.53 | -50.47 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.